Nitric Oxide, NO for short, is a widespread signaling molecule that participates in virtually every cellular and organ function in the body. In the lungs, inhaled NO is responsible for smooth muscle relaxation (which dilates blood vessels), and body-wide, it is involved in regulation of inflammation, thrombosis and proliferation.
NO has protective and beneficial effects in many disease states, especially in diseases of the vascular system.
Inhaled Nitric Oxide
Inhaled NO is used as a potent therapeutic agent in the treatment of pulmonary hypertension and hypoxemia. Its selective vasodilation properties, enable effective oxygenation without affecting systemic blood pressure.
Inhaled nitric oxide (iNO) was first used in neonatal practices in 1992 and has subsequently been used extensively in the management of neonates and children with cardiorespiratory failure, especially in treating Persistent Pulmonary Hypertension of the Newborn (PPHN). In addition, it has been used in pulmonary vasoreactivity testing in cardiac catheterization laboratories, as well as in the treatment of perioperative pulmonary hypertension in congenital heart disease, cardiac transplant and certain other heart failure conditions. Usage has been well established in ICU settings.
Recent randomized controlled studies have also shown iNO's utility in the treatment of COVID-19 and other types of ARDS, as well as for acute lung injury and respiratory failure.
Uniqueness & Innovation
Our patent portfolio (2 granted patents and 4 additional applications) covers several novel aspects of our platform including the plasma generator method (“Plasmatron”) and the highly accurate sensors and algorithms that guarantee safe and efficacious iNO delivery.
Current solutions require high maintenance, with frequent calibration and component replacements. As a result, accuracy is often compromised and logistic burden is high.
Innohale's solutions have been designed to significantly improve resilience over time with minimal maintenance required. The plasmatron design operates at high voltage and low current which could potentially offer life-time durability.
The gas analysis is achieved by proprietary optical sensors which do not require calibration and are significantly more durable than chemical sensors used in other iNO systems today.
Cutting-edge on-demand NO production – concentrations up 2000 ppm
Reliable and precise built-in monitoring of delivered gasses
Effective NO2 reduction
Automatic iNO dosing and titration
Resilience and minimal maintenance